| Identification | Back Directory | [Name]
Fluphenazine decanoate dihydrochloride | [CAS]
2376-65-0 | [Synonyms]
Fluphenazine Decanoate Dihydrochloride (100 mg)
Fluphenazine Decanoate Dihydrochloride (1280803)
Fluphenazine decanoate dihydrochloride - Prolixin Decanoate dihydrochloride
Decanoic acid,2-[4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl ester, dihydrochloride
Fluphenazine decanoate dihydrochlorideQ: What is
Fluphenazine decanoate dihydrochloride Q: What is the CAS Number of
Fluphenazine decanoate dihydrochloride Q: What is the storage condition of
Fluphenazine decanoate dihydrochloride | [Molecular Formula]
C32H45ClF3N3O2S | [MOL File]
2376-65-0.mol | [Molecular Weight]
628.24 |
| Hazard Information | Back Directory | [Uses]
Fluphenazine decanoate dihydrochloride USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Fluphenazine Decanoate
- Fluphenazine Decanoate Injection
| [in vivo]
Fluphenazine decanoate dihydrochloride (0.22 mg/kg and followed by 0.33 mg/kg; i.m.; 8 times every 3 weeks), as an antipsychotic, increases sensitivity to dopamine on monkey model following extended treatment[2].
Fluphenazine decanoate dihydrochloride (25 mg/kg; i.m.; 6 times every 3 weeks; 24 weeks) induces mouth movements in the rat, serves as a pharmacological model of human tardive dyskinesia[3].
Fluphenazine decanoate dihydrochloride (1, 2, 3 mg/kg/d; s.c.; 60 d) shows antifertility effects and induces hyperprolactinemia concomitant with gonadotropin suppression in adult male rat[4].
| Animal Model: | Cebus apella monkey[2] | | Dosage: | 0.22 mg/kg and followed by 0.33 mg/kg | | Administration: | Intramuscular injection; 8 times per 3 weeks; 0.22 mg/kg for 63 weeks and 0.33 mg/kg for 6 weeks | | Result: | Decreased the aggressiveness composite behavioral variables (CBV).
Resulted stereotypic behavior induced by agonist and decreased prolactin response to AMPH.
|
| Animal Model: | Male Sprague-Dawley rats (250 g)[3] | | Dosage: | 25 mg/kg | | Administration: | Intramuscular injection into the hind limb; 24 weeks | | Result: | Resulted in spontaneous vacuous chewing mouth movements and jaw tremor.
|
| Animal Model: | Adult male rats[4] | | Dosage: | 1, 2, 3 mg/kg/d | | Administration: | Subcutaneous injection between 10:00-12:00 h; 60 days | | Result: | Increased serum prolactin level and suppressed serum LH and FSH levels at day 60.
Increased hypothalamic tyrosine hydroxylase levels, enhanced chromatin decondensation, and resulted DNA denaturation.
|
| [IC 50]
D2 Receptor |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
| Company Name: |
Pharma Affiliates
|
| Tel: |
172-5066494 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList694812/0_EN.htm |
|